Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2248 in Hepatitis C Infection
NCT02161510Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of MK-2248 in hepatitis C (HCV) (10 arms), sponsored by Merck & Co. Primary endpoints: Maximum change from baseline in Viral Load, Number of participants experiencing an adverse event and 1 more. Started Jul 2014; status: completed.
02
Drugs
MK-2248
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02161510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161510.